William Blair Issues Pessimistic Forecast for CRGX Earnings

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Equities researchers at William Blair cut their Q1 2025 earnings per share estimates for shares of CARGO Therapeutics in a report issued on Thursday, March 13th. William Blair analyst S. Corwin now expects that the company will earn ($0.76) per share for the quarter, down from their prior estimate of ($0.66). William Blair has a “Market Perform” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.69) per share. William Blair also issued estimates for CARGO Therapeutics’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.39) EPS and FY2025 earnings at ($2.03) EPS.

A number of other brokerages have also recently issued reports on CRGX. Chardan Capital cut CARGO Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. lowered CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Thursday, January 30th. Truist Financial lowered CARGO Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $32.00 to $7.00 in a research note on Thursday, January 30th. HC Wainwright lowered CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, January 30th. Finally, Piper Sandler lowered CARGO Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $34.00 to $4.00 in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $15.00.

CARGO Therapeutics Stock Performance

Shares of CRGX opened at $3.80 on Monday. The stock’s 50-day simple moving average is $6.72 and its 200 day simple moving average is $14.35. The stock has a market capitalization of $175.00 million, a price-to-earnings ratio of -0.89 and a beta of 1.65. CARGO Therapeutics has a 52-week low of $3.00 and a 52-week high of $28.13.

Hedge Funds Weigh In On CARGO Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CRGX. Red Tree Management LLC bought a new position in CARGO Therapeutics during the 4th quarter worth approximately $30,293,000. TRV GP VI LLC bought a new position in CARGO Therapeutics during the 4th quarter worth approximately $26,924,000. TRV GP V LLC purchased a new stake in CARGO Therapeutics in the 4th quarter worth approximately $25,051,000. Geode Capital Management LLC lifted its holdings in CARGO Therapeutics by 80.6% in the 3rd quarter. Geode Capital Management LLC now owns 838,279 shares of the company’s stock worth $15,469,000 after buying an additional 374,018 shares during the period. Finally, Sio Capital Management LLC purchased a new stake in CARGO Therapeutics in the 3rd quarter worth approximately $3,208,000. 93.16% of the stock is currently owned by institutional investors.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.